Skip to main content
OpenTrials
Completed

NCT Number: NCT00334711

Sulfonylurea Response in Patients With Diabetes Due to Kir6.2 Mutations

The purpose of this study is to investigate whether patients with diabetes due to Kir6.2 mutations can be treated with sulfonylurea medication rather than insulin, and if this is the case to investigate the mechanism for sulfonylurea response.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Diabetes Mellitus Endocrine System Diseases Glucose Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diabetes due to KCNJ11 (Kir6.2) mutation

Exclusion criteria

  • None

Treatment and study plan

Sulfonylurea

Drug

Primary outcomes

  1. HbA1c reduction

Secondary outcomes

  1. insulin secretory response to intravenous glucose

  2. insulin secretory response to oral glucose

  3. insulin secretory response to mixed meal (sustacal)

  4. Incidence of Hypoglycemia

Sponsors and collaborators

Lead sponsor

Royal Devon and Exeter NHS Foundation Trust

Other

Collaborators

  • Haukeland University Hospital
  • Hôpital Necker-Enfants Malades
  • Wellcome Trust

Registry information

Official study title

A Prospective Study of Sulfonylureas in Patients With Diabetes Due to Kir6.2 Mutations

Important dates

Study start
2004
Study completion
2006
First posted
Jun 8, 2006
Registry last updated
Nov 29, 2006

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.